

REVIEW-ASSESSMENT

From

**Assoc.Prof. Dimitar Kaley, M.D., Ph.D.
Head of Division of medical oncology and radiotherapy
SBALOZS "Dr. Marko Markov"-Varna**

On

**Criteria and indicators of
Jeliazko Iliev Arabadjiev, M.D., Ph.D.
Head of department of medical oncology
Acibadem City Clinic Tokuda hospital - Sofia**

**For participation in competition for
Academic position "Associate Professor" in Oncology
For the needs of Department of medical oncology
Acibadem City Clinic Tokuda hospital - Sofia**

I. Normative grounds of the review

I have been selected as a member of a scientific jury and as an official reviewer of a competition for Associate Professor with candidate Jeliazko Iliev Arabadjiev, M.D., Ph.D. My election was announced on the basis of a decision of the Scientific Council of Acibadem City Clinic Tokuda Hospital, Protocol № 33 / 27.10.2020 and Order № 02 / 05.01.2021 of the Executive Director of Acibadem City Clinic Tokuda Hospital.

II. Professional and creative biography of the candidate

Dr. Jeliazko Arabadjiev was born on November 15, 1973. He graduated with a master's degree (doctor of human medicine) from the Medical University Prof. Dr. P. Stoyanov - Varna in 1997. Since October 2013 he has been an assistant at the Clinic of Medical Oncology in USBALO - Sofia, since October 2015 is a senior physician in the Department of Medical Oncology, Acibadem City Clinic Tokuda Hospital, and since June 2018 is its head. Acquired a specialty in Medical Oncology in 2014. Since March 2019 he is a doctoral student in the Department of Oncology, Medical University - Varna, and in 2020 he defended his dissertation for the degree of "Ph.D." on the topic: Predictive and prognostic value of tumor-infiltrating lymphocytes in women with breast cancer. In addition, he holds a master's degree in Health Management from 2012. In the period 2008-2019 he conducted 8 qualification courses, including specializations in behavior in breast cancer and thyroid cancer, respectively, at the Bordet Institute, Brussels, Belgium, and the University of Pisa, Italy. He is a member of the Expert Council in the medical specialty "Medical Oncology" under the Minister of Health and on the expert boards of the MORE 2019, 2020, 2021, developing clinical guidelines based on evidence. In the period 2015-2019 he was a national representative in the European Society of Medical Oncology (ESMO). He is a member of the European Society of Medical Oncology (ESMO), the American Association of Clinical Oncology (ASCO), the American Association for Clinical Trials (AACR), the Bulgarian Association of Medical Oncology (BAMO), the Bulgarian Association of Oncodermatology (BADO) and the Bulgarian clinical trials (BACP).

III. Normative documentation for participation in the competition

The candidate submits all documents required by the competition: CV, copies of diploma for educational and scientific degree doctor, copies of diploma for the acquired specialty in Medical Oncology, document for work experience in the specialty, list of scientific papers and publications, lists and evidence of participation in scientific forums in Bulgaria and abroad, summaries of participation in scientific forums, author's reference for scientific contributions of the submitted works, reference for impact factor, list of citations, criminal record and medical certificate.

IV. Scientific production participating in the competition

IV.A. Dissertation thesis for scientific degree "PhD". The topic of the dissertation is: Predictive and prognostic value of tumor-infiltrating lymphocytes in women with breast cancer; the defense is with a certificate № 109-588 / 24.09.2020 of the Medical University - Varna. It is presented in a volume of 120 pages, contains 22 tables, 31 figures and a reference with 246 titles. Formulates 9 conclusions and 6 contributions of scientific-theoretical and scientific-practical nature.

IV.B. Expert activity. Dr. Jeliazko Arabadjiev is a participant in two international projects: CEE Uro-Oncology collaborative group, dedicated to prostate cancer, and Think Tank on ovarian cancer, dedicated to ovarian cancer. He also participates in a national project: Study of PIK3CA mutations in Bulgaria and a scientific survey.

IV.C. Scientometric indicators. In the competition for associate professor Dr. Jeliazko Arabadjiev presents a total of 59 publications, of which 2 monographs, 7 participations in chapters of books, textbooks and studies, 29 publications in Bulgarian periodicals, 1 publication in international periodicals and 13 reports and communications presented at national and foreign forums. In terms of authorship in 19 publications, the candidate is the first or sole author.

(1) Textbooks (monographs, textbooks, manuals). Dr. Jeliazko Arabadjiev is the author of two monographs: (i) Immunological strategies and treatment of breast cancer (2020) and (ii) Drug toxicity from immunotherapy in the treatment of cancer (2020). He is a co-author of 3 textbooks for continuing education in medical oncology and 2 evidence-based national clinical guidelines: (i) Behavior in rare non-epithelial ovarian tumors; Textbook Clinical Behavior in Ovarian Cancer; (ii) Art in the cytotoxic treatment of ovarian cancer - present and future; Textbook Clinical Behavior in Ovarian Cancer; (iii) PARP inhibition in metastatic prostate cancer - biological justification and therapeutic efficacy; Textbook Behavior in prostate cancer; (iv) Current therapeutic scenarios for advanced urothelial carcinoma; Textbook Behavior in urothelial carcinoma; (v) Prevention of bone loss in hormone therapy; Clinical guidance Behavior in prostate cancer; (vi) Hormone therapy in biochemical progression after treatment; Clinical guidance Behavior in prostate cancer; (vii) Handbook to help cancer patients and their relatives.

(2) Scientific articles. This category of scientific production is represented by 37 publications in medical periodicals. One of them was published in a foreign medical journal.

All publications could be structured as follows: 7 in Bulgarian periodicals related to the dissertation, 29 original articles in Bulgarian periodicals not related to the dissertation and one in a foreign journal not related to the dissertation. In 19 of all publications Dr. Jeliazko Arabadjiev is the first author.

The scientific articles are published in the following journals: BioScience Trends, Medic Plus, PRO Medic, MEDINFO, Medical Magazine, MD, STUDIA Oncologia, Oncology, Medical Examination and MEDICART.

(3) Participation in scientific forums (congresses, conferences and symposia), etc. Participations with reports and / or posters in 13 scientific forums at home and abroad are presented, presented with abstracts - 11 Bulgarian (2 of them with international participation) and 2 international forums.

(4) Impact factor. Dr. Jeliazko Arabadjiev has a publication in a referenced international journal with an impact factor. The total impact factor evaluating the candidate's scientific output is 1,553.

(5) Citation. The list of citations (self-discovered) includes 23 references. According the official statement from CMB 5 citations are found - 3 in Scopus and 2 in Web of knowledge

V. Interpretation of the applicant's scientific contributions

The main aspect in the scientific production of Dr. Jeliazko Arabadjiev is the tumor immunocompromise in solid neoplasms, especially in breast cancer, in the light of modern personalized oncology.

His dissertation analyzes prognostic and predictive parameters associated with tumor-infiltrating lymphocytes in breast cancer. Special emphasis is placed on some correlations and algorithms for personalization of adjuvant modalities - chemotherapy, endocrine therapy and radiotherapy.

A real upgrade of the topic of the dissertation are the two monographs, especially Immunological Strategies and Treatment of Breast Cancer, whose content develops and explores the idea of the immune landscape around cancer and for the first time in Bulgarian oncology demonstrates immunooncological clinical thinking. The second monograph Drug toxicity from immunotherapy in the treatment of oncological diseases summarizes for the first time in Bulgaria the toxicological potential of immunotherapeutic agents and formulates models for pharmacological modulation and protection of side effects.

Dr. Jeliazko Arabadjiev's erudition in the field of precise oncology is further represented by his authorship in publications on some predictive biomarkers, especially on BRCA in breast cancer, ovarian and prostate cancer and on EGFR (T790M), ALK and ROS1 in non-small cell lung cancer, carcinoma.

The four publications of the candidate in the Textbooks of the MORE conference are a kind of scientific and clinical detailing. All of them form in the Bulgarian medical oncology the most modern paradigms for precise medicine, define the highest international standards through stratified recommendation and incorporate them as methods for continuing medical education.

In summary: the scientific presence of Dr. Jeliazko Arabadjiev in the Bulgarian medical oncology has accents of current topics, methodological competence, analytical interpretability and clinical applicability.

VI. Teaching and editorial activities

The candidate works as a part-time assistant at Sofia University St. Kliment Ohridski, Sofia. He worked as an assistant in SBALO - Sofia for the period 2013-2015. Participates in teaching and training of resident doctors in oncology.

Dr. Arabadjiev is a member of several prestigious editorial boards: European Journal of Medicine (in the period 2016-2019), Medinfo, Medical Magazine, Medic Pro, Medic GP, Medical News and Health Navigator.

VII. Healing activity

Dr. Jeliazko Arabadjiev has over 18 years of work experience, of which 6.5 years are as a medical oncologist. His professional career covers all aspects of malignant solid tumors in adults.

VIII. Conclusion

Based on the significant scientific contribution in the field of Bulgarian medical oncology, academic erudition and clinical expertise of Jeliazko Arabadjiev MD, PhD, I propose to the esteemed scientific jury to choose him as Associate Professor at the Department of Medical Oncology, Acibadem City Clinic Tokuda Hospital.

25 Jan 2021

Reviewer:



Assoc. Prof. Dimitar Kalev, M.D., Ph.D.

REVIEW-ASSESSMENT

From

Assoc.Prof. Dimitar Kalev, M.D., Ph.D.
Head of Division of medical oncology and radiotherapy
SBALOZS "Dr. Marko Markov"-Varna

On

Criteria and indicators of
Jeliazko Iliev Arabadjiev, M.D., Ph.D.
Head of department of medical oncology
Acibadem City Clinic Tokuda hospital - Sofia

For participation in competition for
Academic position "Associate Professor" in Oncology
For the needs of Department of medical oncology
Acibadem City Clinic Tokuda hospital - Sofia

I. Normative grounds of the review

I have been selected as a member of a scientific jury and as an official reviewer of a competition for Associate Professor with candidate Jeliazko Iliev Arabadjiev, M.D., Ph.D. My election was announced on the basis of a decision of the Scientific Council of Acibadem City Clinic Tokuda Hospital, Protocol № 33 / 27.10.2020 and Order № 02 / 05.01.2021 of the Executive Director of Acibadem City Clinic Tokuda Hospital.

II. Professional and creative biography of the candidate

Dr. Jeliazko Arabadjiev was born on November 15, 1973. He graduated with a master's degree (doctor of human medicine) from the Medical University Prof. Dr. P. Stoyanov - Varna in 1997. Since October 2013 he has been an assistant at the Clinic of Medical Oncology in USBALO - Sofia, since October 2015 is a senior physician in the Department of Medical Oncology, Acibadem City Clinic Tokuda Hospital, and since June 2018 is its head. Acquired a specialty in Medical Oncology in 2014. Since March 2019 he is a doctoral student in the Department of Oncology, Medical University - Varna, and in 2020 he defended his dissertation for the degree of "Ph.D." on the topic: Predictive and prognostic value of tumor-infiltrating lymphocytes in women with breast cancer. In addition, he holds a master's degree in Health Management from 2012. In the period 2008-2019 he conducted 8 qualification courses, including specializations in behavior in breast cancer and thyroid cancer, respectively, at the Bordet Institute, Brussels, Belgium, and the University of Pisa, Italy. He is a member of the Expert Council in the medical specialty "Medical Oncology" under the Minister of Health and on the expert boards of the MORE 2019, 2020, 2021, developing clinical guidelines based on evidence. In the period 2015-2019 he was a national representative in the European Society of Medical Oncology (ESMO). He is a member of the European Society of Medical Oncology (ESMO), the American Association of Clinical Oncology (ASCO), the American Association for Clinical Trials (AACR), the Bulgarian Association of Medical Oncology (BAMO), the Bulgarian Association of Oncodermatology (BADO) and the Bulgarian clinical trials (BACP).

III. Normative documentation for participation in the competition

The candidate submits all documents required by the competition: CV, copies of diploma for educational and scientific degree doctor, copies of diploma for the acquired specialty in Medical Oncology, document for work experience in the specialty, list of scientific papers and publications, lists and evidence of participation in scientific forums in Bulgaria and abroad, summaries of participation in scientific forums, author's reference for scientific contributions of the submitted works, reference for impact factor, list of citations, criminal record and medical certificate.

IV. Scientific production participating in the competition

IV.A. Dissertation thesis for scientific degree "PhD". The topic of the dissertation is: Predictive and prognostic value of tumor-infiltrating lymphocytes in women with breast cancer; the defense is with a certificate № 109-588 / 24.09.2020 of the Medical University - Varna. It is presented in a volume of 120 pages, contains 22 tables, 31 figures and a reference with 246 titles. Formulates 9 conclusions and 6 contributions of scientific-theoretical and scientific-practical nature.

IV.B. Expert activity. Dr. Jeliazko Arabadjiev is a participant in two international projects: CEE Uro-Oncology collaborative group, dedicated to prostate cancer, and Think Tank on ovarian cancer, dedicated to ovarian cancer. He also participates in a national project: Study of PIK3CA mutations in Bulgaria and a scientific survey.

IV.C. Scientometric indicators. In the competition for associate professor Dr. Jeliazko Arabadjiev presents a total of 59 publications, of which 2 monographs, 7 participations in chapters of books, textbooks and studies, 29 publications in Bulgarian periodicals, 1 publication in international periodicals and 13 reports and communications presented at national and foreign forums. In terms of authorship in 19 publications, the candidate is the first or sole author.

(1) Textbooks (monographs, textbooks, manuals). Dr. Jeliazko Arabadjiev is the author of two monographs: (i) Immunological strategies and treatment of breast cancer (2020) and (ii) Drug toxicity from immunotherapy in the treatment of cancer (2020). He is a co-author of 3 textbooks for continuing education in medical oncology and 2 evidence-based national clinical guidelines: (i) Behavior in rare non-epithelial ovarian tumors; Textbook Clinical Behavior in Ovarian Cancer; (ii) Art in the cytotoxic treatment of ovarian cancer - present and future; Textbook Clinical Behavior in Ovarian Cancer; (iii) PARP inhibition in metastatic prostate cancer - biological justification and therapeutic efficacy; Textbook Behavior in prostate cancer; (iv) Current therapeutic scenarios for advanced urothelial carcinoma; Textbook Behavior in urothelial carcinoma; (v) Prevention of bone loss in hormone therapy; Clinical guidance Behavior in prostate cancer; (vi) Hormone therapy in biochemical progression after treatment; Clinical guidance Behavior in prostate cancer; (vii) Handbook to help cancer patients and their relatives.

(2) Scientific articles. This category of scientific production is represented by 37 publications in medical periodicals. One of them was published in a foreign medical journal.

All publications could be structured as follows: 7 in Bulgarian periodicals related to the dissertation, 29 original articles in Bulgarian periodicals not related to the dissertation and one in a foreign journal not related to the dissertation. In 19 of all publications Dr. Jeliazko Arabadjiev is the first author.

The scientific articles are published in the following journals: BioScience Trends, Medic Plus, PRO Medic, MEDINFO, Medical Magazine, MD, STUDIA Oncologia, Oncology, Medical Examination and MEDICART.

(3) Participation in scientific forums (congresses, conferences and symposia), etc. Participations with reports and / or posters in 13 scientific forums at home and abroad are presented, presented with abstracts - 11 Bulgarian (2 of them with international participation) and 2 international forums.

(4) Impact factor. Dr. Jeliazko Arabadjiev has a publication in a referenced international journal with an impact factor. The total impact factor evaluating the candidate's scientific output is 1,553.

(5) Citation. The list of citations (self-discovered) includes 23 references. According the official statement from CMB 5 citations are found - 3 in Scopus and 2 in Web of knowledge

V. Interpretation of the applicant's scientific contributions

The main aspect in the scientific production of Dr. Jeliazko Arabadjiev is the tumor immunocompromise in solid neoplasms, especially in breast cancer, in the light of modern personalized oncology.

His dissertation analyzes prognostic and predictive parameters associated with tumor-infiltrating lymphocytes in breast cancer. Special emphasis is placed on some correlations and algorithms for personalization of adjuvant modalities - chemotherapy, endocrine therapy and radiotherapy.

A real upgrade of the topic of the dissertation are the two monographs, especially Immunological Strategies and Treatment of Breast Cancer, whose content develops and explores the idea of the immune landscape around cancer and for the first time in Bulgarian oncology demonstrates immunooncological clinical thinking. The second monograph Drug toxicity from immunotherapy in the treatment of oncological diseases summarizes for the first time in Bulgaria the toxicological potential of immunotherapeutic agents and formulates models for pharmacological modulation and protection of side effects.

Dr. Jeliazko Arabadjiev's erudition in the field of precise oncology is further represented by his authorship in publications on some predictive biomarkers, especially on BRCA in breast cancer, ovarian and prostate cancer and on EGFR (T790M), ALK and ROS1 in non-small cell lung cancer. carcinoma.

The four publications of the candidate in the Textbooks of the MORE conference are a kind of scientific and clinical detailing. All of them form in the Bulgarian medical oncology the most modern paradigms for precise medicine, define the highest international standards through stratified recommendation and incorporate them as methods for continuing medical education.

In summary: the scientific presence of Dr. Jeliazko Arabadjiev in the Bulgarian medical oncology has accents of current topics, methodological competence, analytical interpretability and clinical applicability.

VI. Teaching and editorial activities

The candidate works as a part-time assistant at Sofia University St. Kliment Ohridski, Sofia. He worked as an assistant in SBALO - Sofia for the period 2013-2015. Participates in teaching and training of resident doctors in oncology.

Dr. Arabadjiev is a member of several prestigious editorial boards: European Journal of Medicine (in the period 2016-2019), Medinfo, Medical Magazine, Medic Pro, Medic GP, Medical News and Health Navigator.

VII. Healing activity

Dr. Jeliazko Arabadjiev has over 18 years of work experience, of which 6.5 years are as a medical oncologist. His professional career covers all aspects of malignant solid tumors in adults.

VIII. Conclusion

Based on the significant scientific contribution in the field of Bulgarian medical oncology, academic erudition and clinical expertise of Jeliazko Arabadjiev MD, PhD, I propose to the esteemed scientific jury to choose him as Associate Professor at the Department of Medical Oncology, Acibadem City Clinic Tokuda Hospital.

25 Jan 2021

Reviewer:



Assoc. Prof. Dimitar Kalev, M.D., Ph.D.